NH-sulfoximine: A novel pharmacological inhibitor of the mitochondrial F1 Fo -ATPase, which suppresses viability of cancerous cells.
Daniela StrobbeRosalba PecorariOriana ConteAntonella MinutoloChristine M M HendriksStefan WiezorekDanilo FaccendaRosella AbetiCarla MontesanoCarsten BolmMichelangelo CampanellaPublished in: British journal of pharmacology (2020)
The novel sulfoximine analogue of BTB-06584, NHS, acts as a selective pharmacological inhibitor of the mitochondrial F1 Fo -ATPase. NHS, by blocking the hydrolysis of ATP perturbs the bioenergetic homoeostasis of cancer cells, leading to a non-apoptotic type of cell death.